Cross-talk between the thyroid and liver: A new target for nonalcoholic fatty liver disease treatment

被引：28
作者：
Huang, Yue-Ye [1 ]
Gusdon, Aaron M. [3 ]
Qu, Shen [1 ,2 ]
机构：
[1] Tongji Univ, Shanghai Peoples Hosp 10, Dept Endocrinol & Metab, Sch Med, Shanghai 200072, Peoples R China
[2] Nanjing Med Univ, Dept Endocrinol & Metab, Nanjing 210029, Jiangsu, Peoples R China
[3] Weill Cornell Med Coll, Dept Neurol & Neurosci, New York, NY 10065 USA
来源：
WORLD JOURNAL OF GASTROENTEROLOGY | 2013年 / 19卷 / 45期
关键词：
Thyroid hormone; Thyroid hormone receptor; Nonalcoholic fatty liver disease; Obesity; HORMONE RECEPTOR-BETA; HEPATIC INSULIN-RESISTANCE; BONE-MINERAL DENSITY; BROWN ADIPOSE-TISSUE; AGONIST GC-1; ALPHA-GENE; TR-BETA; METABOLIC SYNDROME; NUCLEAR RECEPTOR; BODY-WEIGHT;
D O I：
10.3748/wjg.v19.i45.8238
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Nonalcoholic fatty liver disease (NAFLD) has been recognized as the most common liver metabolic disease, and it is also a burgeoning health problem that affects one-third of adults and is associated with obesity and insulin resistance now. Thyroid hormone (TH) and its receptors play a fundamental role in lipid metabolism and lipid accumulation in the liver. It is found that thyroid receptor and its isoforms exhibit tissue-specific expression with a variety of functions. TR beta 1 is predominantly expressed in the brain and adipose tissue and TR beta 2 is the major isoform in the liver, kidney and fat. They have different functions and play important roles in lipid metabolism. Recently, there are many studies on the treatment of NAFLD with TH and its analogues. We review here that thyroid hormone and TR are a potential target for pharmacologic treatments. Lipid metabolism and lipid accumulation can be regulated and reversed by TH and its analogues. (C) 2013 Baishideng Publishing Group Co., Limited. All rights reserved.
引用
收藏
页码：8238 / 8246
页数：9
相关论文
共 85 条
  • [1] Thyroid Hormone Regulates Hepatic Expression of Fibroblast Growth Factor 21 in a PPARα-dependent Manner
    Adams, Andrew C.
    Astapova, Inna
    Fisher, Ffolliott M.
    Badman, Michael K.
    Kurgansky, Katherine E.
    Flier, Jeffrey S.
    Hollenberg, Anthony N.
    Maratos-Flier, Eleftheria
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2010, 285 (19) : 14078 - 14082
  • [2] Amir M, 2011, EXPERT REV GASTROENT, V5, P159, DOI [10.1586/EGH.11.4, 10.1586/egh.11.4]
  • [3] A TRβ-selective agonist confers resistance to diet-induced obesity
    Amorim, Beatriz S.
    Ueta, Cintia B.
    Freitas, Beatriz C. G.
    Nassif, Renata J.
    de Azevedo Gouveia, Cecilia Helena
    Christoffolete, Marcelo A.
    Moriscot, Anselmo S.
    Lancelloti, Carmen Lucia
    Llimona, Flavia
    Barbeiro, Hermes Vieira
    de Souza, Heraldo Possolo
    Catanozi, Sergio
    Passarelli, Marisa
    Aoki, Marcelo S.
    Bianco, Antonio C.
    Ribeiro, Miriam O.
    [J]. JOURNAL OF ENDOCRINOLOGY, 2009, 203 (02) : 291 - 299
  • [4] Thyroid hormone receptor β mutants:: Dominant negative regulators of peroxisome proliferator-activated receptor γ action
    Araki, O
    Ying, H
    Furuya, F
    Zhu, XG
    Cheng, SY
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (45) : 16251 - 16256
  • [5] Selective activation of thyroid hormone signaling pathways by GC-1: a new approach to controlling cholesterol and body weight
    Baxter, JD
    Webb, P
    Grover, G
    Scanlan, TS
    [J]. TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2004, 15 (04) : 154 - 157
  • [6] Structural basis of GC-1 selectivity for thyroid hormone receptor isoforms
    Bleicher, Lucas
    Aparicio, Ricardo
    Nunes, Fabio M.
    Martinez, Leandro
    Gomes Dias, Sandra M.
    Migliorini Figueira, Ana Carolina
    Morim Santos, Maria Auxiliadora
    Venturelli, Walter H.
    da Silva, Rosangela
    Donate, Paulo Marcos
    Neves, Francisco A. R.
    Simeoni, Luiz A.
    Baxter, John D.
    Webb, Paul
    Skaf, Munir S.
    Polikarpov, Igor
    [J]. BMC STRUCTURAL BIOLOGY, 2008, 8
  • [7] ALPHA-THYROID AND BETA-THYROID HORMONE-RECEPTOR (TR) GENE-EXPRESSION DURING AUDITORY NEUROGENESIS - EVIDENCE FOR TR ISOFORM-SPECIFIC TRANSCRIPTIONAL REGULATION IN-VIVO
    BRADLEY, DJ
    TOWLE, HC
    YOUNG, WS
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (02) : 439 - 443
  • [8] BRADLEY DJ, 1992, J NEUROSCI, V12, P2288
  • [9] Anti-obesity, anti-diabetic, and lipid lowering effects of the thyroid receptor β subtype selective agonist KB-141
    Bryzgalova, Galina
    Effendic, Suad
    Khan, Akhtar
    Rehnmark, Stefan
    Barbounis, Peter
    Boulet, Jamie
    Dong, Gao
    Singh, Rajni
    Shapses, Sue
    Malm, Johan
    Webb, Paul
    Baxter, John D.
    Grover, Gary J.
    [J]. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2008, 111 (3-5) : 262 - 267
  • [10] The dominant negative thyroid hormone receptor β mutant Δ337T alters PPARα signaling in heart
    Buroker, Norman E.
    Young, Martin E.
    Wei, Caimiao
    Serikawa, Kyle
    Ge, Ming
    Ning, Xue-Han
    Portman, Michael A.
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2007, 292 (02): : E453 - E460
123456789